Antibody-Conjugate Targeting TACSTD2 for Polycystic Kidney Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatment options for polycystic kidney disease (PKD), particularly autosomal dominant polycystic kidney disease (ADPKD), are limited and lack age-inclusivity, with no FDA-approved therapies for adolescents, children, or infants.
Innovation Solution
Development of a method involving the administration of an antibody-therapeutic conjugate that targets a marker of cystic epithelium, such as TACSTD2, combined with a therapeutic drug, to treat PKD across all age groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug therapy is used for ADPKD, then modest benefits are achieved, but significant side effects occur
Solution Approach 1:
The patent uses an antibody as an intermediary agent that specifically binds to TACSTD2 on cystic epithelium cells. This antibody mediates the delivery of therapeutic payloads (such as radionuclides, toxins, or chemotherapeutic agents) selectively to cyst cells, thereby achieving therapeutic benefits while minimizing systemic side effects. The antibody acts as a targeted delivery vehicle that bridges the gap between systemic administration and localized action.
2Adaptability or versatility
If existing FDA-approved therapies are used, then treatment is available for adults, but no therapy is available for adolescents, children, or infants
Solution Approach 1:
The patent develops a universal therapeutic platform based on antibody-targeted therapy that can be applied across all age groups affected by ADPKD. The antibody-conjugate system is designed to be adaptable for use in adolescents, children, and infants, making the therapy universally applicable regardless of patient age. This multi-functional approach allows a single therapeutic mechanism to serve diverse pediatric and adult populations.
3Measurement precision
If non-specific drug therapy is administered, then treatment reaches all kidney tissue, but it cannot specifically target cystic epithelium
Solution Approach 1:
The patent employs antibodies with specific affinity for TACSTD2, a marker expressed on cystic epithelium cells. This confers local quality or specificity to the therapy, enabling it to selectively bind to and act upon cyst cells while leaving normal renal tissue unaffected. The antibody's specific binding properties create a localized therapeutic effect precisely where needed - on the cystic epithelium - thereby achieving both high targeting specificity and therapeutic effectiveness.
Data Source
AI summary
The disclosure herein provides, in example embodiments, methods of treating a subject in need thereof, e.g., a subject with polycystic kidney disease (PKD), for example, with an antibody-drug conjugate comprising, e.g., tumor-associated calcium signal transducer 2 protein (TACSTD2).